Scientific Reports · 2022 · 31 citations · 54 references
Life SciencesBioinformaticsBiomedical SciencesDrug DiscoveryMolecular VirologyTranscriptomicsAntiviral TherapyDisease Network BiologyHost-pathogen Interaction NetworksMulti-omics Data FusionNetwork-based Biomarker DiscoveryAntiviral TherapeuticsBlood-based BiomarkersDisease Diagnostic BiomarkersHost Cell Cycle Manipulation By VirusesHost Interaction NetworksHost-disease Interaction NetworksIntegrative GenomicsSars-cov-2 Infection
COVID-19 is a global pandemic impacting the daily living of millions. As variants of the virus evolve, a complete comprehension of the disease and drug targets becomes a decisive duty. The Omicron variant, for example, has a notably high transmission rate verified in 155 countries. We performed integrative transcriptomic and network analyses to identify drug targets and diagnostic biomarkers and repurpose FDA-approved drugs for SARS-CoV-2. Upon the enrichment of 464 differentially expressed genes, pathways regulating the host cell cycle were significant. Regulatory and interaction networks featured hsa-mir-93-5p and hsa-mir-17-5p as blood biomarkers while hsa-mir-15b-5p as an antiviral agent. MYB, RRM2, ERG, CENPF, CIT, and TOP2A are potential drug targets for treatment. HMOX1 is suggested as a prognostic biomarker. Enhancing HMOX1 expression by neem plant extract might be a therapeutic alternative. We constructed a drug-gene network for FDA-approved drugs to be repurposed against the infection. The key drugs retrieved were members of anthracyclines, mitotic inhibitors, anti-tumor antibiotics, and CDK1 inhibitors. Additionally, hydroxyquinone and digitoxin are potent TOP2A inhibitors. Hydroxyurea, cytarabine, gemcitabine, sotalol, and amiodarone can also be redirected against COVID-19. The analysis enforced the repositioning of fluorouracil and doxorubicin, especially that they have multiple drug targets, hence less probability of resistance.
54
Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction Networks
Paul Shannon, Andrew Markiel, Owen Ozier et al. · Genome Research · 2003 · 54.3K citations · Full text
Damian Szklarczyk, Annika L. Gable, David Lyon et al. · Nucleic Acids Research · 2018 · 19.2K citations · Full text
pROC: an open-source package for R and S+ to analyze and compare ROC curves
Xavier Robin, Natacha Turck, Alexandre Hainard et al. · BMC Bioinformatics · 2011 · 14K citations · Full text